Clinical Trial: Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia

U.S., April 7 -- ClinicalTrials.gov registry received information related to the study (NCT07512700) titled 'Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia' on March 29.

Brief Summary: This study is a multicenter, randomized, prospective Phase II clinical trial designed to compare the effectiveness of two treatment approaches for patients with acute monocytic leukemia.

Study Start Date: Sept. 01, 2025

Study Type: INTERVENTIONAL

Condition: Acute Monocytic Leukemia

Intervention: DRUG: CACAG+VEN

Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor

1. Azacytidine (75 mg/m2/day, days 1 to 7).

2. Cytarabine (75-100 mg/m2 every 12 hrs, da...